The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an hTERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an α-chain and a second polypeptide comprising a variable region of a β-chain of a T-cell receptor (TCR), and wherein:(a) the variable region of an α-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4； and(b) the variable region of a β-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7.Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules.The present invention has utility in the treatment of cancer.本發明提供一種核酸分子，其編碼在由II類主要組織相容性複合體(MHC)呈現hTERT肽時能夠結合該肽之特異性結合分子，該hTERT肽包含SEQ ID NO: 1中所闡述之胺基酸序列，其中該特異性結合分子包含含有T細胞受體(TCR)之α鏈之可變區的第一多肽及含有β鏈之可變區的第二多肽，且其中：(a) α鏈之該可變區包含CDR序列CDR1、CDR2及CDR3，該等CDR序列分別包含SEQ ID NO: 2、3及4中所闡述之胺基酸序列；及(b) β鏈之該可變區包含CDR序列CDR1、CDR2及CDR3，該等CDR序列分別包含SEQ ID NO: 5、6及7中所闡述之序列。亦提供包含此類核酸分子之重組構築體、載體及宿主細胞，與由此類核酸分子編碼之特異性結合分子。本發明在治療癌症中具有效用。
